United Therapeutics Co. (NASDAQ:UTHR) Director Raymond Dwek Sells 3,000 Shares

United Therapeutics Co. (NASDAQ:UTHR) Director Raymond Dwek sold 3,000 shares of the business’s stock in a transaction on Monday, April 21st. The shares were sold at an average price of $285.57, for a total transaction of $856,710.00. Following the completion of the sale, the director now directly owns 1,750 shares in the company, valued at $499,747.50. This represents a 63.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Raymond Dwek also recently made the following trade(s):

• On Monday, April 14th, Raymond Dwek sold 3,000 shares of United Therapeutics stock. The shares were sold at an average price of $285.16, for a total value of $855,480.00.
• On Monday, April 7th, Raymond Dwek sold 4,000 shares of United Therapeutics stock. The stock was sold at an average price of $284.55, for a total value of $1,138,200.00.

United Therapeutics Stock Up 3.0 %

Shares of NASDAQ UTHR opened at $292.82 on Wednesday. United Therapeutics Co. has a twelve month low of $233.28 and a twelve month high of $417.82. The company has a market cap of $13.15 billion, a PE ratio of 12.86, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63. The business’s 50 day moving average price is $313.33 and its two-hundred day moving average price is $347.74.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. During the same quarter last year, the firm posted $4.36 EPS. As a group, research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Signaturefd LLC boosted its holdings in shares of United Therapeutics by 4.7% during the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock worth $234,000 after acquiring an additional 30 shares during the period. Parallel Advisors LLC boosted its stake in United Therapeutics by 2.8% in the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock valued at $385,000 after purchasing an additional 30 shares during the period. Anchor Investment Management LLC grew its holdings in United Therapeutics by 12.0% in the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 30 shares in the last quarter. Great Lakes Advisors LLC increased its position in United Therapeutics by 1.6% during the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock worth $697,000 after buying an additional 31 shares during the period. Finally, Oregon Public Employees Retirement Fund increased its position in United Therapeutics by 0.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock worth $3,214,000 after buying an additional 33 shares during the period. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of recent research reports. JPMorgan Chase & Co. reduced their price target on United Therapeutics from $357.00 to $355.00 and set an “overweight” rating for the company in a research report on Monday. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, April 17th. HC Wainwright reiterated a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a research note on Thursday, February 27th. UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Finally, Bank of America upgraded United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 target price on the stock in a report on Monday. Three research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $395.67.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.